Table of Contents
What is Respiratory Syncytial Virus (RSV)?
Respiratory Syncytial Virus (RSV) is a common virus that primarily affects the lungs, making it difficult to breathe. It is most prevalent in infants, premature babies, and adults with poor health, but it can also affect older, healthy adults. It spreads through direct contact such as sneezing, coughing, sharing food, cups, or eating utensils, and touching used tissues. RSV can also spread by touching the nose or mouth after coming into contact with an infected person. Symptoms vary based on age, with older children and healthy adults typically experiencing mild, cold-like symptoms. However, in infants, premature babies, and older adults with preexisting lung and heart diseases, the symptoms can be more serious. It’s worth noting that RSV cannot be treated with antibiotics, and a mild case usually resolves itself after about two weeks if left untreated.
RSV and Its Long-Term Effects in Adults
In adults, especially those with compromised immune systems or preexisting conditions, RSV can have serious implications. Research suggests that RSV may contribute to the development of chronic respiratory conditions in adults. These long-term effects include an increased risk of developing respiratory conditions such as asthma, chronic obstructive pulmonary disease (COPD), and pneumonia. In addition, RSV infection can lead to persistent respiratory symptoms, reduced lung function, and an increased risk of hospitalization. In fact, studies have found a 2-4-fold increased risk of RSV hospitalization in adults with COPD, ischemic heart disease (IHD), stroke and diabetes, and a 1.5-3-fold increased risk in adults with asthma.
RSV Infections: Risk and Prevalence
RSV infections primarily circulate during the fall and winter seasons, coinciding with the flu season. Infections typically peak during January and February each year. For most adults, RSV manifests in the form of a mild cold or flu, but in high-risk groups, it can cause severe conditions like pneumonia and bronchiolitis. The virus remains contagious for the first three to eight days following infection and can survive on nonporous surfaces for between three and 30 hours. While urgent care centers can test for RSV, treatment usually focuses on addressing the symptoms rather than testing for a specific virus.
Preventive Measures and Vaccination
Basic hygiene practices like frequent hand washing, avoiding close contact with sick individuals, covering coughs and sneezes, and staying home when unwell are effective preventive measures. The good news is that an RSV vaccine has been approved by the U.S. Food and Drug Administration (FDA). This vaccine, which received FDA approval in May 2023, is recommended for infants, young children, pregnant individuals, and adults aged 60 years and older and is expected to be available from the fall of 2023.
Conclusion
Recognizing RSV as a potential cause of long-term respiratory issues in adults is essential. It is prudent for healthcare providers to factor in the long-term effects of RSV when treating adults, especially those with preexisting conditions. With the availability of the new RSV vaccine, the hope is to reduce the impact of this virus on the adult population and prevent the development of chronic respiratory conditions in the long term.
